GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Cyclically Adjusted Book per Share

Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Cyclically Adjusted Book per Share : $12.33 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Alnylam Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2023 was $-1.754. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $12.33 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Alnylam Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -3.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Alnylam Pharmaceuticals was 23.40% per year. The lowest was 3.20% per year. And the median was 12.40% per year.

As of today (2024-04-28), Alnylam Pharmaceuticals's current stock price is $143.31. Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $12.33. Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 11.62.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 25.16. The lowest was 4.66. And the median was 12.85.


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.45 11.21 12.30 12.73 12.33

Alnylam Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.73 12.74 12.63 12.55 12.33

Competitive Comparison of Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alnylam Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.754/129.4194*129.4194
=-1.754

Current CPI (Dec. 2023) = 129.4194.

Alnylam Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 12.651 99.695 16.423
201406 12.346 100.560 15.889
201409 11.796 100.428 15.201
201412 12.127 99.070 15.842
201503 17.770 99.621 23.085
201506 16.663 100.684 21.419
201509 15.602 100.392 20.113
201512 14.863 99.792 19.276
201603 13.913 100.470 17.922
201606 12.837 101.688 16.338
201609 11.834 101.861 15.036
201612 10.708 101.863 13.605
201703 9.654 102.862 12.146
201706 12.246 103.349 15.335
201709 11.463 104.136 14.246
201712 17.723 104.011 22.052
201803 17.466 105.290 21.469
201806 16.116 106.317 19.618
201809 14.639 106.507 17.788
201812 12.868 105.998 15.711
201903 14.539 107.251 17.544
201906 15.814 108.070 18.938
201909 14.436 108.329 17.246
201912 12.824 108.420 15.308
202003 11.927 108.902 14.174
202006 12.103 108.767 14.401
202009 10.461 109.815 12.329
202012 8.729 109.897 10.280
202103 7.894 111.754 9.142
202106 7.196 114.631 8.124
202109 6.327 115.734 7.075
202112 4.894 117.630 5.385
202203 3.323 121.301 3.545
202206 1.455 125.017 1.506
202209 -0.550 125.227 -0.568
202212 -1.277 125.222 -1.320
202303 -2.087 127.348 -2.121
202306 -3.268 128.729 -3.286
202309 -1.322 129.860 -1.318
202312 -1.754 129.419 -1.754

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Alnylam Pharmaceuticals  (NAS:ALNY) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alnylam Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=143.31/12.33
=11.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Alnylam Pharmaceuticals was 25.16. The lowest was 4.66. And the median was 12.85.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Alnylam Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals (Alnylam Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Executives
Michael W Bonney director 65 HAYDEN AVE, LEXINGTON MA 02421
Pushkal Garg officer: CMO & EVP Dev & Med Affairs C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Akshay Vaishnaw officer: SVP, Clinical Research 300 THIRD STREET, CAMBRIDGE MA 02139
Yvonne Greenstreet officer: EVP, Chief Commercial Officer PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton officer: Chief Financial Officer 300 THIRD STREET, CAMBRIDGE MA 02142
Tolga Tanguler officer: EVP, Chief Commercial Officer 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Indrani Lall Franchini officer: EVP, CLO & Secretary C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Dennis A Ausiello director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
Phillip A Sharp director BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Maraganore director, officer: President and CEO 75 SIDNEY ST, CAMBRIDGE MA 02139
Laurie Keating officer: SVP,GC & Secretary 300 THIRD STREET, CAMBRIDGE MA 02142
Steven M Paul director C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285